GH Research (NASDAQ:GHRS) Trading Up 0.6% – What’s Next?

GH Research PLC (NASDAQ:GHRS) traded up 0.6% during mid-day trading on Friday . The company traded as high as $9.05 and last traded at $8.67. 20,249 shares changed hands during trading, a decline of 74% from the average session volume of 79,364 shares. The stock had previously closed at $8.62.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.

GH Research Price Performance

The firm has a market capitalization of $448.48 million, a PE ratio of -12.94 and a beta of 0.74. The firm’s fifty day simple moving average is $7.80 and its 200-day simple moving average is $10.45.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, analysts predict that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its stake in GH Research PLC (NASDAQ:GHRS) by 11.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,251,714 shares of the company’s stock after acquiring an additional 664,381 shares during the quarter. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities & Exchange Commission. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).